Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 6,240,000 shares, a growth of 33.3% from the April 30th total of 4,680,000 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 2,080,000 shares, the short-interest ratio is currently 3.0 days.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

TAK traded down $0.03 during trading hours on Friday, reaching $14.97. The company's stock had a trading volume of 1,625,742 shares, compared to its average volume of 1,937,972. The company's 50-day moving average is $14.66 and its 200-day moving average is $14.10. Takeda Pharmaceutical has a 52 week low of $12.58 and a 52 week high of $15.43. The firm has a market cap of $47.62 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The company had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. On average, equities analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new stake in Takeda Pharmaceutical in the 1st quarter valued at $37,000. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $52,000. Cromwell Holdings LLC bought a new position in Takeda Pharmaceutical during the fourth quarter worth about $61,000. Finally, Venturi Wealth Management LLC increased its position in Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after acquiring an additional 4,260 shares during the period. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.